Aytu BioPharma delays Q2 FY2023 filing due to warrant accounting matter; believes no impact on revenue, cash, or EBITDA

AYTU BIOPHARMA, INC

Delayed filing of Form 10-Q for quarter ended Dec 31, 2022 pending management review of warrant accounting from prior financings.
Company states the matter will not affect assets, cash, revenue, cost of goods sold, operating expenses, loss from operations, or adjusted EBITDA.
Quarterly conference call rescheduled; company intends to file the quarterly report as soon as practicable.
No restatement or adjustment to previously reported financial metrics expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.